Patent · US Active

Immunoconjugates and methods

US12268750B2 · kind B2 · utility

0Cited by
51References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 30, 2024
Grant dateApr 8, 2025
Priority date
Expiry dateAug 30, 2044

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer. Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n   (I)

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.